Tourmaline Bio, Inc. Common Stock
Compare this stock
TRML Stock Report Card
$
86%
Performance
Score:
100/100
TRML returned 56.10% in the last 12 months. Based on SPY's performance of 13.09%, its performance is above average giving it a score of 100 of 100.
Volatility
Score:
67/100
TRML has had a higher than average amount of volatility over the last 12 months giving it a score of 66 of 100.
Tourmaline Bio, Inc. Common Stock Summary
Nasdaq / TRML
Healthcare
Biotechnology
Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune diseases. It develops medicines and therapies for the Atherosclerotic cardiovascular disease (ASCVD) and Thyroid Eye Disease (TED). The company was incorporated in 2021 and is based in New York, New York.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Checkout Similar Companies
TRML scored highly on our reportcard. Here are some similar companies and how they performed.
